Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

v3.5.0.2
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Consolidated Statements Of Operations        
Revenues
Operating expenses:        
Amortization & depreciation 185 369
General and administrative 111,852 103,960 202,291 189,231
Total operating expenses 111,852 104,145 202,291 189,600
Loss from operations (111,852) (104,145) (202,291) (189,600)
Other income (expense):        
Gain (Loss) on fair value adjustment - derivatives 25,456
Gain on debt reversal 485 485
Interest expense (38,445) (57,104) (110,229) (112,518)
Interest expense - beneficial conversion feature (7,500) (6,250) (11,250)
Total other income (expense) (38,445) (64,119) (116,479) (97,827)
Loss before provision for income taxes (150,297) (168,264) (318,770) (287,427)
Provision for income tax
Net loss (150,297) (168,264) (318,770) (287,427)
Less: Net loss attributable to noncontrolling interest 1,052 933 2,123 1,867
Net loss attributable to TranBioTec, Inc. $ (149,245) $ (167,331) $ (316,647) $ (285,560)
Net loss per share        
(Basic and fully diluted) $ (0.002) $ (0.003) $ (0.005) $ (0.005)
Weighted average number of common shares outstanding 67,751,068 58,655,062 66,885,683 58,536,520